+91-8668442535

Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market By Infection (Cellulitis, Abscess, Surgical Wounds, & Traumatic Wound), By Type Of Drug (Delafloxacin, Vancomycin, Ceftaroline Fosamil, Telvancin & Others), By Pathogens (MSSA, MRSA, Beta-Hemolytic Streptococcus, Escherichia Coli & Others) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

The report titled "Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall ABSSSI treatment market along with the market size and estimates for the duration 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of infection, pathogen, drug, and different geographies. According to market experts, acute skin and skin structure infections (ABSSSI) comprise a set of bacterial infections that involve multiple layers of the skin and associated tissues. These infections tend to be more severe in nature than simple infections of the skin, and they usually require systemic antibacterial therapy and patient hospitalization. The majority of ABSSSIs are caused by gram-positive bacterial strains, especially Staphylococcus aureus. Gram-negative bacteria, on the other hand, are extremely important in certain types of infections as well as in hospital settings.

The global ABSSSI treatment market is divided into Delafloxacin, Vancomycin, Ceftaroline Fosamil, Telvancin, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, TMP-SMZ, and Others for the purposes of this study. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global ABSSSI treatment market is also segmented on the basis of type of infection into cellulitis, abscess, boil, cyst, surgical wound, and traumatic wound. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global ABSSSI treatment market is classified according to pathogen type, which includes Methicillin-sensitive Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and Others. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The geographical segmentation of the ABSSSI treatment market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The ABSSSI treatment market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Furiex Pharmaceuticals, Inc., GlaxoSmithKline plc, Melinta Therapeutics, Inc., Debiopharm International S.A., MerLion Pharmaceuticals Pte Ltd., Durata Therapeutics, Inc., Paratek Pharmaceuticals, Inc., and Cempra, Inc., among others.

Based on the type of infection, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

  • Cellulitis
  • Abscess/Boil/Cyst
  • Surgical Wound
  • Traumatic Wound

In 2016, cellulitis was observed as the largest segment due to key driving factors such as the rising prevalence of multiple drug-resistant bacteria, increasing hospitalization due to medical awareness, mounting cases of hospital-acquired infection, and incessant research and development activities observed in the ABSSSI treatment market. Although the exact incidence of the disease is unknown, a few American studies have identified 24.6 cases per 1,000 people per year as potentially affected by cellulitis, accounting for 37.3% of the hospitalized population. During the forecast period of 2017–2025, surgical wounds are expected to grow at a significant rate due to key driving factors such as the rising prevalence of surgical site infections, the introduction of stringent policies associated with hospital environments by government agencies, and rising awareness associated with early diagnosis and treatment among physicians to treat multiple resistant bacterial infections.

Based on the type of drug, the global acute bacterial skin and skin structure infection (ABSSSI) treatment market are segmented as follows:

  • Delafloxacin
  • Vancomycin
  • Ceftaroline family
  • Telavancin
  • Oritavancin
  • Tedizolid
  • Daptomycin
  • Tigecycline
  • Linezolid
  • TMP-SMZ
  • Others (Doxycycline, Levofloxacin, Metronidazole, and Others)

In 2016, vancomycin was observed as the largest market segment as it is the most preferred drug in the treatment of multiple resistant bacterial infections. The rising prevalence of nosocomial infections, high awareness associated with skin diseases and early diagnosis, and incessant research and development activities in the field of ABSSSI treatment In the near future, delafloxacin is expected to be the fastest-growing drug due to its exclusive approval against ABSSSI and high efficiency compared to existing drugs. The brand name of delafloxacin is Baxdela, owned by Melinta Therapeutics; according to studies, delafloxacin is a fluoroquinolone with activity against both gram-positive and gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and is available in both intravenous (IV) and oral formulations.

Based on the type of pathogen, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

  • Methicillin-sensitive Staphylococcus aureus (MSSA)
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Beta-hemolytic Streptococcus
  • Escherichia coli
  • Enterococcus faecalis
  • Pseudomonas aeruginosa
  • Others

In 2016, MSSA and MRSA accounted for more than 50% of the market share due to key drivers such as the rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital-acquired infections, and incessant research and development in the field of ABSSSI treatment. According to the American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult. Thus, the prevalence of hospital-acquired infections is increasing, coupled with the stringent regulations and policies adopted by government bodies against hospitals that lack the means to maintain a sterile environment.

Based on the type of pathogen, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

  • Methicillin-sensitive Staphylococcus aureus (MSSA)
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Beta-hemolytic Streptococcus
  • Escherichia coli
  • Enterococcus faecalis
  • Pseudomonas aeruginosa
  • Others

In 2016, MSSA and MRSA accounted for more than 50% of the market share due to key drivers such as the rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital-acquired infections, and incessant research and development in the field of ABSSSI treatment. According to the American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult. Thus, the prevalence of hospital-acquired infections is increasing, coupled with the stringent regulations and policies adopted by government bodies against hospitals that lack the means to maintain a sterile environment.

Frequently Asked Questions:

The market for Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment is expected to reach XX Bn in 2025.

The Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment market is expected to see significant CAGR growth over the coming years,at 9.8%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Furiex Pharmaceuticals Inc.,GlaxoSmithKline plc,Melinta Therapeutics, Inc.,Debiopharm International S.A.,MerLion Pharmaceuticals Pte Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2017
Category:  Pharmaceuticals
Report ID:   58628
Report Format:   PDF
Pages:   120
Rating:    4.8 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support